VX-668 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 231 | α1−アンチトリプシン欠乏症 | 1 |
231. α1−アンチトリプシン欠乏症
臨床試験数 : 93 / 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05727800 (ClinicalTrials.gov) | February 8, 2023 | 3/2/2023 | A Phase 1, First-in-human Study of VX-668 | A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668 | Alpha-1 Antitrypsin Deficiency | Drug: VX-668;Drug: Placebo | Vertex Pharmaceuticals Incorporated | NULL | Recruiting | 18 Years | 55 Years | All | 114 | Phase 1 | United States |